BACKGROUND: Women with polycystic ovary syndrome (PCOS) have a greater clustering of cardiac risk factors. However, the link between PCOS and cardiovascular (CV) disease is incompletely described. OBJECTIVE: The aim of this analysis was to evaluate the risk of CV events in 390 postmenopausal women enrolled in the National Institutes of Health-National Heart, Lung, and Blood Institute (NIH-NHLBI) sponsored Women's Ischemia Syndrome Evaluation (WISE) study according to clinical features of PCOS. METHODS: A total of 104 women had clinical features of PCOS defined by a premenopausal history of irregular menses and current biochemical evidence of hyperandrogenemia. Hyperandrogenemia was defined as the top quartile of androstenedione (> or = 701 pg/ml), testosterone (> or = 30.9 ng/dl), or free testosterone (> or = 4.5 pg/ml). Cox proportional hazard model was fit to estimate CV death or myocardial infarction (n = 55). RESULTS: Women with clinical features of PCOS were more often diabetic (P < 0.0001), obese (P = 0.005), had the metabolic syndrome (P < 0.0001), and had more angiographic coronary artery disease (CAD) (P = 0.04) compared to women without clinical features of PCOS. Cumulative 5-yr CV event-free survival was 78.9% for women with clinical features of PCOS (n = 104) vs. 88.7% for women without clinical features of PCOS (n = 286) (P = 0.006). PCOS remained a significant predictor (P < 0.01) in prognostic models including diabetes, waist circumference, hypertension, and angiographic CAD as covariates. CONCLUSION: Among postmenopausal women evaluated for suspected ischemia, clinical features of PCOS are associated with more angiographic CAD and worsening CV event-free survival. Identification of postmenopausal women with clinical features of PCOS may provide an opportunity for risk factor intervention for the prevention of CAD and CV events.
BACKGROUND:Women with polycystic ovary syndrome (PCOS) have a greater clustering of cardiac risk factors. However, the link between PCOS and cardiovascular (CV) disease is incompletely described. OBJECTIVE: The aim of this analysis was to evaluate the risk of CV events in 390 postmenopausal women enrolled in the National Institutes of Health-National Heart, Lung, and Blood Institute (NIH-NHLBI) sponsored Women's Ischemia Syndrome Evaluation (WISE) study according to clinical features of PCOS. METHODS: A total of 104 women had clinical features of PCOS defined by a premenopausal history of irregular menses and current biochemical evidence of hyperandrogenemia. Hyperandrogenemia was defined as the top quartile of androstenedione (> or = 701 pg/ml), testosterone (> or = 30.9 ng/dl), or free testosterone (> or = 4.5 pg/ml). Cox proportional hazard model was fit to estimate CV death or myocardial infarction (n = 55). RESULTS:Women with clinical features of PCOS were more often diabetic (P < 0.0001), obese (P = 0.005), had the metabolic syndrome (P < 0.0001), and had more angiographic coronary artery disease (CAD) (P = 0.04) compared to women without clinical features of PCOS. Cumulative 5-yr CV event-free survival was 78.9% for women with clinical features of PCOS (n = 104) vs. 88.7% for women without clinical features of PCOS (n = 286) (P = 0.006). PCOS remained a significant predictor (P < 0.01) in prognostic models including diabetes, waist circumference, hypertension, and angiographic CAD as covariates. CONCLUSION: Among postmenopausal women evaluated for suspected ischemia, clinical features of PCOS are associated with more angiographic CAD and worsening CV event-free survival. Identification of postmenopausal women with clinical features of PCOS may provide an opportunity for risk factor intervention for the prevention of CAD and CV events.
Authors: C G Solomon; F B Hu; A Dunaif; J Rich-Edwards; W C Willett; D J Hunter; G A Colditz; F E Speizer; J E Manson Journal: JAMA Date: 2001-11-21 Impact factor: 56.272
Authors: N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson Journal: Endocr Relat Cancer Date: 1999-06 Impact factor: 5.678
Authors: C N Merz; S F Kelsey; C J Pepine; N Reichek; S E Reis; W J Rogers; B L Sharaf; G Sopko Journal: J Am Coll Cardiol Date: 1999-05 Impact factor: 24.094
Authors: E O Talbott; D S Guzick; K Sutton-Tyrrell; K P McHugh-Pemu; J V Zborowski; K E Remsberg; L H Kuller Journal: Arterioscler Thromb Vasc Biol Date: 2000-11 Impact factor: 8.311
Authors: B L Sharaf; D O Williams; N J Miele; R P McMahon; P H Stone; P Bjerregaard; R Davies; A D Goldberg; M Parks; C J Pepine; G Sopko; C R Conti Journal: J Am Coll Cardiol Date: 1997-01 Impact factor: 24.094
Authors: B Delia Johnson; Kathleen M Dwyer; Frank Z Stanczyk; Vera Bittner; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; YuChing Yang; Georgina E Hale; C Noel Bairey Merz Journal: J Clin Endocrinol Metab Date: 2010-06-16 Impact factor: 5.958
Authors: Michelle R Jones; Gregorio Chazenbalk; Ning Xu; Angela K Chua; Tamar Eigler; Emebet Mengesha; Yen-Hao Chen; Jung-Min Lee; Marita Pall; Xiaohui Li; Yii-Der I Chen; Kent D Taylor; Ruchi Mathur; Ronald M Krauss; Jerome I Rotter; Richard S Legro; Ricardo Azziz; Mark O Goodarzi Journal: J Clin Endocrinol Metab Date: 2012-06-21 Impact factor: 5.958
Authors: C Noel Bairey Merz; Saralyn Mark; Barbara D Boyan; Alice K Jacobs; Prediman K Shah; Leslee J Shaw; Doris Taylor; Eduardo Marbán Journal: J Womens Health (Larchmt) Date: 2010-06 Impact factor: 2.681
Authors: A D Coviello; W V Zhuang; K L Lunetta; S Bhasin; J Ulloor; A Zhang; D Karasik; D P Kiel; R S Vasan; J M Murabito Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Megha Agarwal; Chrisandra Shufelt; Puja K Mehta; Edward Gill; Daniel S Berman; Debiao Li; Behzad Sharif; Ning Li; C Noel Bairey Merz; Louise E J Thomson Journal: Cardiovasc Diagn Ther Date: 2013-09